Shared on08 Aug 25Fair value Increased 30%
The significant upward revision in Xeris Biopharma Holdings’ price target reflects rising future P/E expectations despite a decline in net profit margin, resulting in a fair value increase from $6.30 to $7.80. What's in the News Xeris Biopharma Holdings raised full-year 2025 total revenue guidance to $280-$290 million from $260-$275 million.